29 Nov 2017 14:19
For release: 29 November 2017
genedrive plc ("genedrive" or the "Company")
Result of AGM
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that at the Annual General Meeting, held in Manchester today, all resolutions proposed were duly passed.
- Ends -
For further details please contact:
genedrive plc | +44 (0)161 989 0245 |
David Budd: CEO | |
Matthew Fowler: CFO | |
Peel Hunt LLP | +44 (0)207 418 8900 |
James Steel | |
Oliver Jackson | |
Consilium Strategic Communications | +44 (0)203 709 5700 |
Chris Gardner | |
Matthew Neal | |
Laura Thornton | |
genedrive@consilium-comms.com |
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has received CE-IVD Certification.
Further details can be found at: www.genedriveplc.com and www.genedrive.com
Genedrive (GDR)